Welcome to the Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) helps accelerate the development of next generation multiple myeloma treatments to extend patient’s lives, and lead to a cure. MMRF brings treatment to multiple myeloma patients 60% faster than the average through collaboration with best in class partners in the US and Internationally. In the process, we are changing the way cancer research is conducted. MMRF, a 501(c)(3), is the number one private funder of multiple myeloma research in the United States.

THE LATEST FROM THE MMRF
Previous
  • precision

    May 29, 2015

    Follow the action at ASCO 2015! Get the latest updates by visiting our ASCO page. Visit now

  • testtube

    May 28, 2015

    Press Release: MMRF & MMRC part of 4 abstracts for presentation at ASCO 2015. Learn more

  • Kathy_minicarousel

    May 27, 2015

    Press Release: Kathy Giusti delivers the 214th Commencement Address to graduating class of UVM. Read more

  • crawfish Boston

    May 27, 2015

    Join Crawfish for Cancer's 3rd Annual Boston Crawfish Boil on June 6. Learn more and get tickets here

  • commungateway

    May 19, 2015

    Connect with patients, engage with experts, get the information you need! MMRF CoMMunity Gateway

  • Tom-Brokaw-book

    May 15, 2015

    Tom Brokaw describes his battle with multiple myeloma in his memoir  A Lucky Life Interrupted.

  • Tri-State 5K

    May 13, 2015

    Tri-State 5K Walk/Run
    Join us on June 7th
    Register Now

Next

KNOWLEDGE LEADS TO CURES. Stay informed with our newsletter.

If you have multiple myeloma,
you have options.

At the MMRF, we’re urgently working to develop treatments to extend your life. We can notify you about clinical trials, connect you to other patients with the same disease characteristics, bring you the latest breaking developments, and more. We’re learning every day. You can too.

LEARN MORE

We Are Beating Multiple Myeloma Now. Join Us.

Multiple myeloma patients have options today because the status quo just a few years ago was, to us, unacceptable.

The model we have created for drug discovery and development is revolutionary. It brings multiple myeloma treatments to trial 60% faster than average. It has resulted in seven multiple myeloma drugs receiving FDA approval in the time it normally takes for one. Through the power of new technology, genomics and immunology, it has extended lives that would have been lost to multiple myeloma yesterday. And it is accelerating all the time. Learn how we are doing it.

To improve the outcome, we partnered with
the best and rewrote the rules.

  • 2015
  • Revlimid® in combination with dexamethasone approved for newly diagnosed multiple myeloma patients
  • 2014
  • 10 clinical trials opened
  • 2014
  • CoMMpass Study enrollment almost completed
  • 2014
  • MMRC launches
    50th clinical trial
  • 2013
  • CoMMunity and Researcher Gateways launched
  • 2013
  • Pomaylast® approved
  • 2012
  • Kyprolis® approved
  • 2011
  • Record 8 treatments in
    Phase III trials
  • 2011
  • MMRF CoMMpassSM launched
  • 2008
  • Doxil approved
  • 2007
  • Revlimid® approved
  • 2006
  • Thalomid® approved
  • 2004
  • MMRC tissue bank established
  • 2004
  • MMRC founded
  • 2003
  • Velcade® approved
  • 2002
  • Zometa® approved
  • 1998
  • MMRF established

The MMRF changed the multiple myeloma treatment
landscape by removing obstacles and injecting speed at each step of
the research and drug development process.